VICO — Vicore Pharma Holding AB Share News
0.000.00%
Last trade - 00:00- SEK2.73bn
- SEK1.83bn
- SEK3.82m
Brief: Vicore Pharma: Digital Therapeutic For IPF Patients
Brief: Vicore Provides An Update On The Attract-3 Covid-19 Trial
Brief: Vicore Pharma Q2 Operating Loss At SEK 64.9 Mln
Brief: Vicore Amends Primary Endpoint To Accelerate Phase 3 Trial In Covid-19 Patients
Brief: Vicore Launches Clinical Study
Brief: Vicore Pharma's Michael Wolff Jensen Resigns As Chairman And Member Of Board Of Directors
Brief: Vicore Initiates Human Forearm Blood Flow Study With C21
Brief: Vicore Pharma Holding Q4 Operating Loss Widens To SEK 81.1 Mln
Brief: Vicore's Air Study Interim Analysis Suggests That C21 Improves Lung Function In IPF Patients
Brief: Vicore says their C21 Treatment Reduces Long-Term Lung Injury After Covid-19
Brief: Vicore Obtains SARS Coronavirus Patent For C21 In US
Brief: Vicore Pharma Holding Q2 Operating Loss Widens To SEK 68.4 Mln
Brief: Vicore Announces FDA Acceptance For Pivotal Phase 3 Trial Of C21 In COVID-19
Brief: Vicore Pharma Holding Q1 Loss For Period Widens To SEK 48.1 Million
Brief: Vicore Starts Collaboration With Alex Therapeutics
Brief: Vicore Pharma: Drug Candidate C21 Dilates Peripheral Resistance Vessels In Fibrotic Disease
Brief: Vicore Pharma Holding Q4 Operating Loss Widens To SEK 58.8 Mln
Brief: Vicore Pharma Completes Directed Share Issue Of SEK 336 Million
Brief: Vicore Pharma Holding: Positive Data From Phase II Study Attract In Patients With COVID-19 Published Online